InGeneron

InGeneron will be attending the Medtech Conference 2024 in Toronto, Canada, from October 15-17, 2024. We look forward to connecting with existing partners and fostering new collaborations to drive the future of regenerative medicine. #Medtech2024 #TorontoMedtech #RegenerativeMedicine #InnovationInHealthcare #MedtechConference #HealthcareInnovation #MedicalDevices #Biotech #FutureOfMedicine

🩺👩⚕️The last two days we at InGeneron had our first physician evening events in Cologne and Frankfurt - how exciting! 🔬We started with a scientific background talk from Dr. Christoph Schmitz on regenerative cells. Followed by a product demonstration of our InGeneron product from Jakob Schmid. Ending with a Q&A session on science, patient accounting and registration. I appreciated the great team effort during these events. Our mission is to help patients suffering from orthopedic diseases to activate their bodies’ own regenerative capabilities. 💪🏼 Looking forward to treating many patients with regenerative cells! 🎉

Unlocking Your Body's Healing Potential: Discover how InGeneron's Transpose® RT platform utilizes your own regenerative cells for tissue repair. Visit our website to learn more about our cell therapy. https://bit.ly/3T98iYo #ingeneron #medicaltechnology #innovation #celltherapy #biotechnology #regenerativemedicine #scienceandtechnology

InGeneron will be attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Francisco from February 12 - 16, 2024. We look forward to connecting with existing partners and fostering new collaborations to drive the future of regenerative medicine. #AAOS2024 #InGeneron #medicaltechnology #innovation #orthopedics

InGeneron reports positive long-term results for its cell therapy in partial-thickness rotator cuff tears. The randomized controlled trial, published in Nature's Scientific Reports, met primary endpoints, and finds statistically significant durable patient benefit 3.4 years post-treatment. To read the full press release, please visit https://bit.ly/3ugBz9q  

InGeneron announces encouraging results from Emory University's 480-Patient Knee Osteoarthritis Trial. Published in Nature Medicine, the study describes InGeneron’s cell therapy as clinically effective and “confirms an exceptional safety profile”. The Phase III clinical trial investigated the efficacy of InGeneron’s regenerative cell therapy in comparison to two other orthobiologic treatments and the conventional corticosteroid injection for knee osteoarthritis. To read the full press release, please visit https://bit.ly/3SnyfDh #ingeneron #medicaltechnology #innovation #celltherapy #biotechnology #regenerativemedicine #scienceandtechnology

InGeneron announces encouraging results from Emory University's 480-Patient Knee Osteoarthritis Trial. Published in Nature Medicine, the study describes InGeneron’s cell therapy as clinically effective and “confirms an exceptional safety profile”. The Phase III clinical trial investigated the efficacy of InGeneron’s regenerative cell therapy in comparison to two other orthobiologic treatments and the conventional corticosteroid injection for knee osteoarthritis. To read the full press release, please visit https://bit.ly/3SnyfDh #ingeneron #medicaltechnology #innovation #celltherapy #biotechnology #regenerativemedicine #scienceandtechnology